Proof-of-concept calculations to determine the health-adjusted life-year trade-off between intravitreal anti-VEGF injections and transmission of COVID-19.
Matt J BoydDaniel Andrew Richard ScottDavid M SquirrellGraham A WilsonPublished in: Clinical & experimental ophthalmology (2020)
Unless COVID-19 prevalence is very high, the reduced disease burden from avoiding visual impairment outweighs the expected HALYs lost from COVID-19 transmission. This finding is driven by the fact that HALYs lost when someone suffers severe visual impairment for 5 years are equivalent to nearly 400 moderate cases of infectious disease lasting 2 weeks each.
Keyphrases
- coronavirus disease
- sars cov
- infectious diseases
- vascular endothelial growth factor
- healthcare
- public health
- risk factors
- respiratory syndrome coronavirus
- mental health
- early onset
- endothelial cells
- density functional theory
- molecular dynamics
- high intensity
- risk assessment
- ultrasound guided
- health information
- optical coherence tomography
- platelet rich plasma